IL-33/sST2 Assay for Respiratory Distress Patient Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IL-33 axis antagonist therapies for treating respiratory diseases do not consistently produce therapeutic effects in all patients due to the lack of a reliable assay to distinguish between different forms of IL-33, making it difficult to predict patient response.
Innovation Solution
A highly sensitive assay is developed to detect reduced IL-33, oxidized IL-33, and bound IL-33/sST2 in biological samples, allowing for the stratification of patients into those likely to benefit from IL-33 axis antagonist therapies based on IL-33/sST2 levels greater than or equal to 25 pg/ml.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a reliable assay to distinguish between different forms of IL-33 is used, then patient response to therapy can be predicted, but the complexity of the diagnostic process increases
Solution Approach 1:
The assay segments the detection of IL-33 by distinguishing between reduced IL-33 and oxidized IL-33 forms using form-specific antibodies. This segmentation allows reliable prediction of patient response to different IL-33 antagonist therapies (ST2 antagonists for reduced form, RAGE antagonists for oxidized form) while maintaining a manageable diagnostic process through targeted detection of specific forms.
2Reliability
If IL-33 axis antagonist therapy is administered to all patients, then more patients may benefit, but treatment effectiveness varies and resources are wasted on non-responders
Solution Approach 1:
The assay performs preliminary detection of IL-33 forms and their complexes (IL-33/sST2, oxidized IL-33/RAGE) before initiating therapy. This preliminary action identifies which patients are likely to respond to IL-33 axis antagonist treatment, allowing clinicians to pre-select appropriate candidates and avoid wasting resources on patients unlikely to benefit.
Solution Approach 2:
The diagnostic approach applies local quality by detecting specific IL-33 forms (reduced vs. oxidized) and their specific complexes in different patient populations. This allows tailored therapy selection - ST2 antagonists for patients with reduced IL-33/sST2 complexes and RAGE antagonists for patients with oxidized IL-33/RAGE complexes - maximizing therapeutic effectiveness while optimizing resource utilization.
3Measurement precision
If the assay detects all forms of IL-33 (reduced, oxidized, and complexes), then comprehensive patient stratification is achieved, but the measurement complexity increases
Solution Approach 1:
The assay uses intermediary antibodies specific to each IL-33 form and complex (anti-reduced IL-33, anti-oxidized IL-33, anti-sST2, anti-RAGE) as mediators to detect and differentiate between reduced IL-33, oxidized IL-33, and their respective complexes. These intermediary reagents enable comprehensive detection with controlled complexity through standardized immunodetection methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay enables personalized treatment strategies by identifying patients who are likely to experience a beneficial therapeutic effect, reducing the likelihood of acute respiratory failure, and potentially preventing death by administering IL-33 axis antagonists to those with elevated IL-33/sST2 levels.
Implementation Method 1
a highly sensitive assay is developed to detect reduced IL-33, oxidized IL-33, and bound IL-33/sST2 in biological samples
Data Source
AI summary
The present disclosure relates to a method of treating a subject suffering from respiratory distress or preventing respiratory distress in a subject at risk thereof with an IL-33 axis antagonist, to a method of determining whether such a subject will respond to treatment with an IL-33 axis antagonist, and to a method of selecting a subject for treatment with an IL-33 axis antagonist, by determining whether the level of IL-33/sST2 in a sample obtained from the subject is greater than or equal to a given reference level. Uses corresponding to said methods are also provided.